Skip to main content

Table 2 Delphi 3 Responses

From: Research priorities in pediatric rheumatology: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus

PROBLEM-TREATMENT MEAN MEDIAN CONFIDENCE INTERVAL AROUND MEDIAN (α = 0.05)
    Lower Limit Upper Limit
Uveitis (JRA, sarcoid, or idiopathic) unresponsive to MTX treated with infliximab 2.86 2 1 3
Systemic onset JRA treated with anakinra 3.68 3 3 4
Pediatric SLE treated with MMF 4.15 4 3 5
JDM unresponsive to prednisone and DMARDS treated with etanercept 4.59 4 4 6
Systemic onset JRA treated with thalidomide 4.28 5 3 5
Thrombocytopenia unresponsive to standard therapy in SLE treated with rituximab 4.57 5 4 5
Localized Scleroderma treated with steroids and MTX 4.88 5 4 6
Pauci-articular JRA with uveitis, with early treatment 6.97 8 8 8
  1. JRA: Juvenile Rheumatoid Arthritis
  2. MTX: Methotrexate
  3. SLE: Systemic Lupus Erythematosus
  4. MMF: Mycophenolate mofetil
  5. JDM: Juvenile Dermatomyositis
  6. DMARDS: Disease-Modifying Anti-Rheumatic Drugs